Head to Head Survey: Kamada (KMDA) vs. The Competition

Kamada (NASDAQ:KMDA) is one of 844 public companies in the “Biotechnology” industry, but how does it compare to its rivals? We will compare Kamada to similar businesses based on the strength of its analyst recommendations, valuation, earnings, risk, dividends, profitability and institutional ownership.

Analyst Recommendations

This is a summary of current ratings and price targets for Kamada and its rivals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Kamada	0	0	4	0	3.00
Kamada Competitors	9873	15284	45615	1598	2.54

Kamada presently has a consensus price target of $13.75, indicating a potential upside of 69.13%. As a group, “Biotechnology” companies have a potential upside of 125.42%. Given Kamada’s rivals higher possible upside, analysts plainly believe Kamada has less favorable growth aspects than its rivals.

Profitability

This table compares Kamada and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Kamada	12.67%	9.36%	6.53%
Kamada Competitors	-12,323.33%	-195.91%	-30.60%

Institutional & Insider Ownership

20.4% of Kamada shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are owned by institutional investors. 36.1% of Kamada shares are owned by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Dividends

Kamada pays an annual dividend of $0.13 per share and has a dividend yield of 1.6%. Kamada pays out 30.2% of its earnings in the form of a dividend. As a group, “Biotechnology” companies pay a dividend yield of 1.3% and pay out 67.4% of their earnings in the form of a dividend. Kamada is clearly a better dividend stock than its rivals, given its higher yield and lower payout ratio.

Earnings and Valuation

This table compares Kamada and its rivals gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Kamada	$180.46 million	$20.20 million	18.91
Kamada Competitors	$702.23 million	$9.48 million	-18.96

Kamada’s rivals have higher revenue, but lower earnings than Kamada. Kamada is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Volatility and Risk

Kamada has a beta of 0.9, meaning that its share price is 10% less volatile than the S&P 500. Comparatively, Kamada’s rivals have a beta of -1.84, meaning that their average share price is 284% less volatile than the S&P 500.

Summary

Kamada beats its rivals on 11 of the 15 factors compared.

About Kamada

Kamada Ltd. is an Israeli biopharmaceutical company that develops, manufactures and markets plasma-derived therapies and specialty pharmaceutical products. Founded in 1990, the company is headquartered in Rehovot, Israel. Its products include Glassia, an alpha-1 proteinase inhibitor used to treat people with alpha-1 antitrypsin deficiency, and immune globulin therapies for conditions including rabies exposure, cytomegalovirus infection and varicella-zoster exposure. Kamada serves markets in the United States and internationally, selling products directly and through commercial partners.